Data Sheet (Cat.No.T12876)

TargetMol
A DRUG SCREENING EXPERT

Seladelpar sodium salt

Chemical Properties



CAS No.:	T12876
Formula:	C21H22F3NaO5S
Molecular Weight:	466.45
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Seladelpar sodium salt is an orally active and specific agonist of PPARδ(EC50 of 2 nM).
Targets(IC_{50})	PPAR-δ: 2 nM (EC50)
In vitro	MBX-8025 is an orally active and specific agonist of PPARδ(EC50 of 2 nM)(750-fold and 2500-fold compared with PPARα or PPARγ receptors, respectively) being developed as a lipid-altering agent[2][3].
In vivo	body weight by ~18% (P<0.05) reduced by Seladelpar sodium salt(in atherogenic diet-fed Wt mice). In contrast, Seladelpar sodium salt produces minimal effect on body weight in atherogenic diet-fed foz/foz mice. Seladelpar sodium salt lowers serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and similarly in Wt mice. Seladelpar sodium salt normalizes serum cholesterol and decreases triglycerides in both genotypes (P<0.05). Seladelpar sodium salt abolishes hepatocyte ballooning (P<0.05) and decreases the nonalcoholic fatty liver disease (NAFLD) activity score by ~50%. Alsosirius red-positive areas in foz/foz mice (P<0.05) significantly reduced by Seladelpar sodium salt [4].

Solubility Information

Solubility	DMSO: 50 mg/mL (107.19 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.144 mL	10.719 mL	21.439 mL
5 mM	0.429 mL	2.144 mL	4.288 mL
10 mM	0.214 mL	1.072 mL	2.144 mL
50 mM	0.043 mL	0.214 mL	0.429 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503.
2. Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97.
3. Choi YJ, et al. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6.
4. Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481